Categories: News

57% of Americans Admit They Would Pay to Move Up in the COVID-19 Vaccination Line According to a ValuePenguin.com Survey

NEW YORK, March 23, 2021 /PRNewswire/ — As COVID-19 vaccinations continue to roll out across the country, many Americans are anticipating their long-awaited turn to get the vaccine. After a year of living in a pandemic, the public’s desire for a COVID-19 shot is producing conflicting feelings. 

ValuePenguin surveyed more than 1,000 consumers and found some are frustrated that high-profile Americans and celebrities have been able to skirt the system to get a vaccine before others, while other Americans admit they would pay to be moved up in the vaccination line. 

Key findings: 

  • While most Americans don’t think people should be able to pay to get a COVID-19 vaccine earlier than normal, 57% admit they’d pay to move up in line.
    • More than 10% would shell out $500 or more to secure a spot.
  • 27% of Americans would give up alcohol for a year if it meant they could get the COVID-19 vaccine tomorrow.
    • Some would also give up Netflix (23%), video games (22%), and watching sports (22%). Consumers were least willing to sacrifice listening to music (10%), sex (14%), shopping (15%), and recreational drugs (16%).
  • More than a quarter (26%) say they’ve taken on a second job to qualify for a COVID-19 vaccine earlier than they would have. An additional 18% will consider doing so.
  • Likewise, 60% think it’s unfair if celebrities and other high-profile individuals have been able to get vaccinated before them.
  • 35% of Americans have felt jealous or resentful toward people in their life who have been vaccinated before them. Gen Xers (50%) and millennials (46%) feel more jealousy than any other generation.

View full report: People Willing to Pay to Move Up in Vaccination Line 

About ValuePenguin.com: ValuePenguin.com, part of LendingTree (NASDAQ: TREE), is a personal finance website that conducts in-depth research and provides objective analysis to help guide consumers to the best financial decisions. ValuePenguin focuses on value, assessing whether the return of a particular decision is worth the cost or risk of that option, and how this stacks up with the other possible choices they may have. For more information, please visit www.valuepenguin.com, like our Facebook page, or follow us on Twitter @ValuePenguin.

Media Contact:
Nadia Gonzalez (Mrs.)
Nadia@LendingTreeNews.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/57-of-americans-admit-they-would-pay-to-move-up-in-the-covid-19-vaccination-line-according-to-a-valuepenguincom-survey-301253516.html

SOURCE ValuePenguin.com

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

3 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

4 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

4 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

5 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago